and congestive heart failure. However, β blockers do not all share the same clinical outcomes with respect to efficacy or safety in many of these conditions. This is especially true in HF ...

BACKGROUND: Limited evidence exists on the prognostic role of continuing medical therapy in patients with heart failure (HF) and an ejection fraction (EF) that has improved over time. This study ...

A new study from the University of Bologna has raised concerns about a common blood pressure medication called beta-blockers.

In patients with heart failure with improved ejection fraction (EF), pharmacological therapy is rarely withdrawn, according ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

Beta-blockers, once contraindicated in heart failure, now represent cornerstone therapy by reducing heart rate, blood pressure, and the detrimental effects of stress hormones on cardiac tissue.

Heart failure is a serious, chronic condition. While medication can help the heart recover and improve its function, this study suggests that the medications themselves may continue to protect the ...

Discover the life-extending approaches to managing heart failure through medication adherence, lifestyle modifications, and ...

However, stopping beta-blocker medication was only associated with a higher risk in patients whose heart function had only moderately improved. "Our results show that heart failure medications ...